feature : StockSummary

when : 사용자가 존재하지 않는 값(예시: 르세라핌 종목)으로 요청했을 때 stockSummary 호출 후 false value(예시 : 셀트리온제약)를 매칭하는 현상

then stockSummary 함수 호출 시 StockSummaryRequest에 companyName을 추가한다.

{ "region": "KR",
 "ticker": "068270", //<- 실제로는 셀트리온 
 "name": "셀바이오텍" }

ticker로 찾은 회사명과 request params의 companyName을 비교하여 false value를 한 번 더 검증

example Q. 르세라핌 종목을 분석해줘. 기대하는 답변 A. 르세라핌이라는 종목이 존재하는 지 확인해주세요. 실제 답변 A. 셀트리온에 대한 분석입니다.

{
  "content": [
    {
      "topicCode": "1",
      "criteria": "시가총액(KRW)",
      "description": "3.17조 원"
    },
    {
      "topicCode": "1",
      "criteria": "시가총액(USD)",
      "description": "24.47억 달러"
    },
    {
      "topicCode": "2",
      "criteria": "BusinessDescription",
      "description": "셀트리온제약 Inc is a Korea-based company engaged in the manufacture and sale of pharmaceuticals.\rThe Company? products include hepatotonics, analgesics, antipyretics, anti-inflammatory drugs, antihistamines, respiratory apparatus drugs, circularly system drugs, digestives and stomachic drugs, hormone disease drugs, antibiotics, nutrients, tonics, and other drugs.\rIt also provides ethical drugs and over-the-counter (OTC) drugs.\rThe Company distributes its products in domestic market and overseas markets such as Philippines, Kazakhstan, Cambodia and other Southeast Asia countries."
    },
    {
      "topicCode": "3",
      "criteria": "BusinessArea",
      "description": "Pharmaceutical Preparation Manufacturing\rMedicinal and Botanical Manufacturing\r"
    },
    {
      "topicCode": "4",
      "criteria": "산업 설명",
      "description": "Generic Pharmaceuticals : The Generic Pharmaceuticals activity consists of companies engaged in manufacturing in-vivo diagnostic substances and pharmaceutical preparations except biological intended for internal and external consumption in dose forms, such as ampoules, tablets, capsules, vials, ointments, powders, solutions, and suspensions."
    },
    {
      "topicCode": "6",
      "criteria": "성과 요약",
      "description": "For the nine months ended 30 September 2023, 셀트리온제약 Inc revenues decreased 1% to 2936.40억 원.\rNet income increased 4% to 205.60억 원.\rRevenues reflect Other Merchandise segment decrease of 26% to 501.10억 원, Other Finished Goods segment decrease of 9% to 1072.80억 원, Kazakhstan segment decrease of 61% to 4.62억 원.\rNet income reflects Commissions decrease of 13% to 144.80억 원 (expense), Miscellaneous Loss decrease of 99% to 910.00만 원 (expense).\rSome( 다음 실적 발표일(Expected) : 2024-03-18)"
    }
  ]
}